Biohaven update on Troriluzole programme - Ataxia UK

Biohaven update on Troriluzole programme

Post Published: July 28, 2023

Biohaven is a pharmaceutical company developing Troriluzole as a treatment for SCA3.

In May 2023, Biohaven submitted a New Drug Application (NDA) to the US regulators (the FDA), to apply for approval of Troriluzole to treat SCA3. Unfortunately, the FDA have decided not to review the NDA, as the primary endpoint for the study was not met. The FDA indicated that Biohaven may request a meeting to discuss the concerns of the FDA.

In their press release, Biohaven state that they are committed to working with the FDA to bring Troriluzole to people with SCA3, and will request a meeting with the FDA.

Read the full press release here.

Subscribe To Our Newsletter

fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Scroll to Top